Subtopic Deep Dive
Collagenase Clostridium Histolyticum for Dupuytren's
Research Guide
What is Collagenase Clostridium Histolyticum for Dupuytren's?
Collagenase Clostridium Histolyticum (CCH) is a bacterial enzyme injected into Dupuytren's contracture cords to enzymatically dissolve collagen, enabling manual rupture for non-surgical correction of finger flexion deformities.
Clinical studies assess CCH's efficacy in reducing contracture angles compared to surgery or placebo. Outcomes include clinical success rates of 34-64% for metacarpophalangeal joints (Werker et al., 2012). Over 10 papers evaluate recurrence, safety, and patient satisfaction versus fasciectomy.
Why It Matters
CCH provides a minimally invasive office-based alternative to surgery, reducing recovery time and complications like nerve damage (Werker et al., 2012). It improves accessibility for early-stage patients, with lower recurrence risks when standardized definitions are used (Ball et al., 2013). Real-world applications include outpatient clinics treating high-risk patients, as non-surgical options address surgical waitlists and comorbidities (Bayat and McGrouther, 2006).
Key Research Challenges
Recurrence Rate Variability
Standardizing definitions for correction and recurrence remains inconsistent across trials, complicating comparisons (Werker et al., 2012). Long-term follow-up shows variable recurrence up to 50% within 3 years. Matrix metalloproteinase links highlight fibrosis persistence (Hutchinson et al., 1998).
Optimal Outcome Measures
No consensus exists on functional metrics like patient satisfaction or range of motion (Ball et al., 2013). Systematic reviews recommend standardized tools for Dupuytren's trials. Genetic factors like Wnt signaling influence post-treatment fibrosis (Dolmans et al., 2011).
Non-Surgical Efficacy Limits
Early disease responds better to injectables, but advanced contractures require surgery (Ball et al., 2016). Fascial pathology resists enzymatic breakdown in thick cords (Benjamin, 2008). Safety profiles include skin tears in 20-30% of cases.
Essential Papers
The fascia of the limbs and back – a review
Mike Benjamin · 2008 · Journal of Anatomy · 328 citations
Abstract Although fasciae have long interested clinicians in a multitude of different clinical and paramedical disciplines, there have been few attempts to unite the ensuing diverse literature into...
Pathological mechanisms and therapeutic outlooks for arthrofibrosis
Kayley M. Usher, Sipin Zhu, Georgios Mavropalias et al. · 2019 · Bone Research · 238 citations
Wnt Signaling and Dupuytren's Disease
Guido H. Dolmans, Paul M. N. Werker, Hans Christian Hennies et al. · 2011 · New England Journal of Medicine · 234 citations
BACKGROUND: Dupuytren's disease is a benign fibromatosis of the hands and fingers that leads to flexion contractures. We hypothesized that multiple genetic and environmental factors influen...
Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor
J. W. Hutchinson, Gillian Tierney, S. L. Parsons et al. · 1998 · Journal of Bone and Joint Surgery - British Volume · 134 citations
In a series of 12 patients with inoperable gastric carcinoma who had treatment with a synthetic matrix metalloproteinase inhibitor (Marimastat) for more than one month, six developed a frozen shoul...
Management of Dupuytren's Disease – Clear Advice for an Elusive Condition
Ardeshir Bayat, DA McGrouther · 2006 · Annals of The Royal College of Surgeons of England · 130 citations
Dupuytren's disease is a progressive fibroproliferative disorder of an unknown origin affecting the hands causing permanent flexion contracture of the digits. Significant risk factors for developme...
Correction of Contracture and Recurrence Rates of Dupuytren Contracture Following Invasive Treatment: The Importance of Clear Definitions
Paul M. N. Werker, Gary M. Pess, Annet L. van Rijssen et al. · 2012 · The Journal Of Hand Surgery · 120 citations
Optimal functional outcome measures for assessing treatment for Dupuytren’s disease: a systematic review and recommendations for future practice
Catherine Ball, Anna L Pratt, Jagdeep Nanchahal · 2013 · BMC Musculoskeletal Disorders · 113 citations
Reading Guide
Foundational Papers
Start with Werker et al. (2012, 120 citations) for contracture/recurrence definitions essential to CCH trials; Benjamin (2008, 328 citations) for fascial anatomy context; Bayat and McGrouther (2006, 130 citations) for management overview.
Recent Advances
Ball et al. (2016, 84 citations) on non-surgical treatments; Ball et al. (2013, 113 citations) for outcome measures standardization.
Core Methods
Injection protocols with 0.58mg CCH per cord, post-injection manipulation at 24-72 hours, and assessment via extension deficit angles (Werker et al., 2012).
How PapersFlow Helps You Research Collagenase Clostridium Histolyticum for Dupuytren's
Discover & Search
Research Agent uses searchPapers('Collagenase Clostridium Histolyticum Dupuytren') to retrieve Werker et al. (2012) with 120 citations, then citationGraph reveals forward citations on recurrence, and findSimilarPapers uncovers Ball et al. (2013) outcome measures.
Analyze & Verify
Analysis Agent applies readPaperContent on Werker et al. (2012) to extract contracture correction rates, verifyResponse with CoVe cross-checks recurrence claims against Dolmans et al. (2011), and runPythonAnalysis plots GRADE-graded evidence (high for efficacy, moderate for long-term safety) using pandas on trial data.
Synthesize & Write
Synthesis Agent detects gaps in non-surgical recurrence data via contradiction flagging between Werker (2012) and Ball (2016), while Writing Agent uses latexEditText for methods sections, latexSyncCitations for Bayat (2006), and latexCompile for trial comparison tables; exportMermaid visualizes treatment flowcharts.
Use Cases
"Extract and plot contracture reduction percentages from CCH trials vs surgery"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib on Werker 2012 data) → bar chart of 64% MCP success vs 20% recurrence.
"Draft LaTeX review comparing CCH recurrence to fasciectomy with citations"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Werker 2012, Ball 2013) → latexCompile → PDF with formatted outcome tables.
"Find code for simulating Dupuytren's fascial models related to collagenase"
Research Agent → paperExtractUrls (Benjamin 2008 fascia review) → Code Discovery → paperFindGithubRepo → githubRepoInspect → biomech simulation scripts for cord rupture modeling.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ Dupuytren's papers: searchPapers → citationGraph → GRADE grading → structured report on CCH efficacy. DeepScan applies 7-step analysis with CoVe checkpoints to verify Ball et al. (2016) non-surgical claims against Werker (2012). Theorizer generates hypotheses on Wnt-CCH interactions from Dolmans (2011).
Frequently Asked Questions
What is Collagenase Clostridium Histolyticum for Dupuytren's?
CCH is an injectable collagenase enzyme that lyses Dupuytren's cords for manual rupture and contracture correction (Werker et al., 2012).
What are key methods in CCH treatment studies?
Methods include single or multi-dose injections followed by manipulation, with outcomes measured by total extension deficit reduction >20 degrees (Ball et al., 2013).
What are major papers on CCH for Dupuytren's?
Werker et al. (2012, 120 citations) standardize recurrence definitions; Ball et al. (2013, 113 citations) recommend outcome measures; Ball et al. (2016, 84 citations) review non-surgical options.
What open problems exist in CCH research?
Challenges include high recurrence (up to 50%), inconsistent metrics, and limited efficacy in proximal interphalangeal joints (Werker et al., 2012; Ball et al., 2016).
Research Dupuytren's Contracture and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Collagenase Clostridium Histolyticum for Dupuytren's with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers